Investment, Funding & Disinvestments

The sale transfers a business that develops and supplies microbiology products used across clinical diagnostics, pharmaceutical manufacturing and food safety testing.

The centres will provide comprehensive services, including antenatal and postnatal care, labour and recovery services, obstetric care, Caesarean sections, theatres, maternal and neonatal intensive care, neonatal intensive care units and post-Caesarean wards.

The initiative aims to help patients with the greatest medical needs access modern therapies within a coordinated framework that complements the UAE’s national health insurance system.

The transaction will be completed through a share purchase agreement with SEVER Life Sciences, under which Alfasigma will acquire 100% of Nordic Group and its subsidiaries.

The complex includes dedicated maternity and paediatric areas, with a total capacity of 66 beds and several functional units designed to improve patient reception, treatment and care.

The investment forms part of BMS’ broader US$ 40 billion commitment to strengthening its US operations, including its manufacturing and research and development (R&D) capabilities.

As part of the transaction, Actio Biosciences will establish a new privately held company dedicated to developing treatments for genetic rare neurological diseases.

The agreement covers joint clinical studies that will combine BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors developed by Revolution Medicines: daraxonrasib, zoldonrasib, elironrasib and RMC-5127.

The study is designed to provide confirmatory evidence for lacutamab in two CTCL subtypes, Sézary syndrome and mycosis fungoides, potentially supporting full regulatory approval.

Vanflyta received approval in China in June 2026 for use in adults with newly diagnosed FLT3-ITD-positive AML, as determined by an appropriate validated diagnostic test.